All In Biotech

Drug Trial Radar · NCT01352221

Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn's Disease (AEGIS-2)

A Prospective, Multicentre, Randomised, Double-blind, Placebo Controlled Study With Oral ST10-021 for the Treatment of Iron Deficiency Anaemia in Subjects With Quiescent Crohn's Disease Where Oral Ferrous Preparations Have Failed or Cannot be Used (AEGIS 2)

Last checked: Nov 20, 2026Latest source record: Oct 30, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 128 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

128

Actual

Start

Aug 2011

Primary completion

Oct 2013

Study completion Oct 2014

Sponsor

Lead sponsor
Shield TherapeuticsIndustry
Sponsor type
Industry
First posted
May 11, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether ST10-021, an oral ferric iron preparation, is safe and effective in the treatment of iron deficiency anaemia (IDA) in subjects with non-active Crohn's Disease (CD).

Conditions

  • Iron Deficiency Anaemia
  • Inflammatory Bowel Disease
  • Crohn's Disease

Interventions

  • ST10Drug

    30 mg capsules to be taken orally twice a day for 12 weeks in double-blind phase

  • Placebo oral capsuleDrug

    Matching placebo capsules for ST10 to be taken orally twice a day for 12 weeks in double-blind phase

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Haemoglobin (Hb) Concentration From Baseline to Week 12 (Full Analysis Set, FAS)Time frame: Baseline to Week 12 - double-blind phase

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.